Bicycle Therapeutics PLC BCYC
We take great care to ensure that the data presented and summarized in this overview for BICYCLE THERAPEUTICS plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BCYC
View all-
Baker Bros. Advisors LP New York, NY9.4MShares$137 Million2.28% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.55MShares$51.6 Million2.97% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.34MShares$34 Million9.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$32.8 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY1.96MShares$28.4 Million0.74% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.85MShares$26.9 Million0.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.72MShares$25 Million0.0% of portfolio
-
Tybourne Capital Management (Hk) LTD Hong Kong, K31.39MShares$20.3 Million11.38% of portfolio
-
Morgan Stanley New York, NY1.35MShares$19.6 Million0.0% of portfolio
-
Candriam S.C.A.1.05MShares$15.3 Million0.14% of portfolio
Latest Institutional Activity in BCYC
Top Purchases
Top Sells
About BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Insider Transactions at BCYC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 16
2024
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
500,000
+4.4%
|
$7,500,000
$15.34 P/Share
|
Dec 13
2024
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
985,397
+2.34%
|
$12,810,161
$13.66 P/Share
|
Nov 11
2024
|
Travis Alvin Thompson CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
6,256
-4.51%
|
$150,144
$24.99 P/Share
|
Nov 11
2024
|
Travis Alvin Thompson CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,575
+3.4%
|
$15,450
$6.63 P/Share
|
Oct 03
2024
|
Travis Alvin Thompson CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
153
-0.66%
|
$3,366
$22.26 P/Share
|
Oct 03
2024
|
Nigel Crockett CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
972
-2.08%
|
$21,384
$22.26 P/Share
|
Oct 03
2024
|
Alistair Milnes CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
972
-1.36%
|
$21,384
$22.26 P/Share
|
Oct 03
2024
|
Michael Skynner CHIEF TECHNOLOGY OFFICER |
SELL
Open market or private sale
|
Direct |
972
-1.04%
|
$21,384
$22.26 P/Share
|
Oct 03
2024
|
Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF |
SELL
Open market or private sale
|
Direct |
247
-1.09%
|
$5,434
$22.26 P/Share
|
Oct 03
2024
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,212
-0.84%
|
$70,664
$22.26 P/Share
|
Jul 03
2024
|
Alistair Milnes CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
967
-1.34%
|
$18,373
$19.64 P/Share
|
Jul 03
2024
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,194
-0.82%
|
$60,686
$19.64 P/Share
|
Jul 03
2024
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
779
-1.24%
|
$14,801
$19.64 P/Share
|
Jul 03
2024
|
Nigel Crockett CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
967
-2.02%
|
$18,373
$19.64 P/Share
|
Jul 03
2024
|
Travis Alvin Thompson CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
148
-0.64%
|
$2,812
$19.64 P/Share
|
Jul 03
2024
|
Michael Skynner CHIEF TECHNOLOGY OFFICER |
SELL
Open market or private sale
|
Direct |
967
-1.02%
|
$18,373
$19.64 P/Share
|
Jul 03
2024
|
Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF |
SELL
Open market or private sale
|
Direct |
246
-1.07%
|
$4,674
$19.64 P/Share
|
Jun 17
2024
|
Baker Bros. Advisors LP |
BUY
Conversion of derivative security
|
Indirect |
2,382,784
+20.07%
|
-
|
Apr 18
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
24,000
+1.09%
|
-
|
Apr 11
2024
|
Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF |
SELL
Open market or private sale
|
Direct |
257
-1.11%
|
$5,654
$22.49 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 339K shares |
---|---|
Conversion of derivative security | 2.38M shares |
Open market or private purchase | 1.49M shares |
Exercise of conversion of derivative security | 2.58K shares |
Open market or private sale | 47.2K shares |
---|